Potentials of ribosomopathy gene as pharmaceutical targets for cancer treatment

Ribosomopathies encompass a spectrum of disorders arising from impaired ribosome biogenesis and reduced functionality.Mutation or dysexpression of the genes that disturb any finely regulated steps of ribosome biogenesis can result in different types of ribosomopathies in clinic,collectively known as ribosomopathy genes.Emerging data suggest that ribosomopathy patients exhibit a significantly heightened susceptibility to cancer.Abnormal ribosome biogenesis and dysregulation of some ribosomopathy genes have also been found to be intimately associated with cancer development.The correlation between ribosome biogenesis or ribosomopathy and the development of malignancies has been well established.This work aims to review the recent advances in the research of ribosomopathy genes among human cancers and meanwhile,to excavate the potential role of these genes,which have not or rarely been reported in cancer,in the disease development across cancers.We plan to establish a theoretical framework between the ribosomopathy gene and cancer development,to further facilitate the potential of these genes as diagnostic biomarker as well as pharmaceutical targets for cancer treatment.

Digital Transformation Trend of the Pharmaceutical Distribution Industry in the Context of New Infrastructure in China

Objective To study the pharmaceutical distribution industry against the background of new infrastructure construction since it is vital to the health and life of the public,and to offer some suggestions to further improve the industry quality and achieve industry upgrading.Methods The national strategies for new infrastructure as well as the underlying logic for enterprise digital transformation were analyzed to provide the outlook on the digital transformation trend of the pharmaceutical distribution industry.Results and Conclusion In the future,the pharmaceutical distribution industry shall transform the pattern,channel,management and control,and experience in the entire business chain in a digital way by focusing on connection efficiency,data efficiency and decision-making efficiency.

Research on the Improvement of Incentive Mechanism for Pharmaceutical Sales Personnel - Taking Company A as an Example

Objective To analyze the improvement of the incentive mechanism of sales personnel in pharmaceutical company A,and to promote the smooth operation and further development of the company in a long term.Methods Compensation incentive,performance appraisal,welfare benefit,training incentive,promotion motivation and enterprise cultural inspiration were explored through questionnaires,telephone interviews and in-person interviews.Results and Conclusion This company’s incentive mechanism has problems in two aspects:Material incentives and spiritual incentives.As to the company’s characteristics and strategic development,the optimization countermeasures of incentive mechanism are proposed from the following three aspects:constructing a reasonable incentive system,establishing an efficient spiritual incentive mechanism,and implementing the dynamic incentive and differentiated incentive simultaneously.

Research on the Threshold Effect of China’s Pharmaceutical Export Trade on Internal and External R&D Investment

Objective To study the threshold effect of export trade on internal and external R&D investment in China’s pharmaceutical industry,and to provide reference for some pharmaceutical enterprises to improve the investment.Methods The panel data of pharmaceutical industry in 25 provinces and cities in China from 2009 to 2019 were selected to conduct empirical analysis by establishing a threshold regression model,and a better export trade interval was obtained.Results and Conclusion There is a threshold value for the effect of new product export on both internal and external R&D expenditures,and the threshold values are 845.2788 million yuan and 318.4198 million yuan,respectively.There is a single threshold effect of export trade on both internal and external R&D investment in China’s pharmaceutical industry,and the effect of export trade on internal and external R&D investment changes from negative to positive as the export trade develops from low to high.

Countermeasures and Suggestions for Strengthening Human Resource Management in China’s Pharmaceutical Industry

Objective To provide reference and enlightenment for the development of human resource management in China’s pharmaceutical industry and to put forward some suggestions to promote the further development of pharmaceutical industry.Methods The method of literature review was used to analyze the current situation and existing problems of human resource management in China’s pharmaceutical industry.Results and Conclusion Only by continuously improving the human resource management skills and innovating management methods can pharmaceutical enterprises achieve long-term benefits with sustainable development.The formulation of human resource management strategy in pharmaceutical industry must be conducive to the realization of the business goals of enterprises.To achieve this overall goal,the human resources management department of enterprises must make the plan from a strategic perspective,formulate talent strategic planning which serves the overall strategic goal of the enterprise.As a result,human resource management will play an important role in the development of China’s pharmaceutical industry.

Comparative Analysis of Profit Model of Typical Pharmaceutical O2O Enterprises in China

Objective To study the profit model of Chinese pharmaceutical O2O enterprises.Methods A case study of three typical pharmaceutical O2O enterprises was conducted,and their profit models were compared.Results and Conclusion The pharmaceutical O2O enterprises in China are divided into three categories according to the profit models.It is found that the current pharmaceutical O2O enterprises have problems such as simple profit model and low corporate profits.Based on these problems,it is recommended that relevant enterprises develop various business models to increase profit channels.Besides,they should establish and improve internal cost control systems.

Research on the Status Quo and Countermeasures of Human Resource Management Outsourcing in China’s Pharmaceutical Enterprises

Objective To explore the current situation of human resource management outsourcing in China’s pharmaceutical enterprises,and to put forward some suggestions for enterprises and the government.Methods The current situation of human resource management outsourcing in China’s pharmaceutical enterprises was analyzed through the method of literature research.Results and Conclusion At present,the status of human resource management outsourcing in China’s pharmaceutical companies is that the level of human resource outsourcing companies is not high,and there are no relevant industry norms and laws.The information asymmetry between pharmaceutical enterprises and outsourcing companies results in adverse selection and moral hazard.Besides,the different culture of pharmaceutical enterprises and outsourcing companies leads to inefficient communication between enterprises and employee.To solve these problems,the government should promote and improve industry norms and laws to regulate the market.In addition,enterprises should clarify the motivation for outsourcing and make good decision on the outsourcing content.Meanwhile,enterprises should strengthen communication with employees to eliminate employees’concerns.

The Development and Experience of American Pharmaceutical Industry Associations and Its Enlightenment to China

Objective To study the development history and current situation of pharmaceutical industry associations in the United State and to provide reference for China’s pharmaceutical industry associations.Methods Literature research and comparative study were used to investigate the development history and current situation of pharmaceutical associations in the United States.Then,their characteristics and experiences were summarized.Some countermeasures and suggestions were put forward for the existing problems of pharmaceutical associations in China.Results and Conclusion The institutional environment of pharmaceutical associations in the United States is relatively good,reflecting the characteristics of emphasizing process management and neglecting entrance management with and the help of public supervision.At the same time,the government advocates market competition by adhering to the market-oriented services for the public.American pharmaceutical industry associations have strong innovation capacity and perfect credit system.Drawing on the experience of pharmaceutical industry associations in the United States,China should strengthen the construction of pharmaceutical industry associations.Firstly,the supervision mechanism should be improved.Secondly,these associations should have good partnerships with the government and offer the public the best services.Finally,the fund-raising mechanism of pharmaceutical industry associations should be optimized to ensure the innovative development of the pharmaceutical industry.

Online pharmaceutical process analysis of Chinese medicine using a miniature mass spectrometer: Extraction of active ingredients as an example

The automation of traditional Chinese medicine(TCM)pharmaceuticals has driven the development of process analysis from offline to online.Most of common online process analytical technologies are based on spectroscopy,making the identification and quantification of specific ingredients still a challenge.Herein,we developed a quality control(QC)system for monitoring TCM pharmaceuticals based on paper spray ionization miniature mass spectrometry(mini-MS).It enabled real-time online qualitative and quantitative detection of target ingredients in herbal extracts using mini-MS without chromatographic separation for the first time.Dynamic changes of alkaloids in Aconiti Lateralis Radix Praeparata(Fuzi)during decoction were used as examples,and the scientific principle of Fuzi compatibility was also investigated.Finally,the system was verified to work stably at the hourly level for pilot-scale extraction.This mini-MS based online analytical system is expected to be further developed for QC applications in a wider range of pharmaceutical processes.

Leveraging Blockchain with Optimal Deep Learning-Based Drug Supply Chain Management for Pharmaceutical Industries

Due to its complexity and involvement of numerous stakeholders,the pharmaceutical supply chain presents many challenges that companies must overcome to deliver necessary medications to patients efficiently.The pharmaceutical supply chain poses different challenging issues,encompasses supply chain visibility,cold-chain shipping,drug counterfeiting,and rising prescription drug prices,which can considerably surge out-of-pocket patient costs.Blockchain(BC)offers the technical base for such a scheme,as it could track legitimate drugs and avoid fake circulation.The designers presented the procedure of BC with fabric for creating a secured drug supplychain management(DSCM)method.With this motivation,the study presents a new blockchain with optimal deep learning-enabled DSCM and recommendation scheme(BCODL-DSCMRS)for Pharmaceutical Industries.Firstly,Hyperledger fabric is used for DSC management,enabling effective tracking processes in the smart pharmaceutical industry.In addition,a hybrid deep belief network(HDBN)model is used to suggest the best or top-rated medicines to healthcare providers and consumers.The spotted hyena optimizer(SHO)algorithm is used to optimize the performance of the HDBN model.The design of the HSO algorithm for tuning the HDBN model demonstrates the novelty of the work.The presented model is tested on the UCI repository’s open-access drug reviews database.

Research on Corporate Social Responsibility Evaluation Based on Improved CRITIC-TOPSIS—A Case Study of Listed Companies in China’s Pharmaceutical Distribution Industry

Corporate social responsibility (CSR) has garnered considerable attention from countries, institutions, enterprises and social groups. However, the lack of research on CSR evaluation system for industries has impeded its development and construction across various industries. Therefore, given the close association of pharmaceutical distribution enterprises with personal health, there exists a pressing need to explore the CSR in this domain. This paper establishes a CSR evaluation index system for pharmaceutical distribution enterprises, employing a combination of documentary analysis and in-depth interviews. This index system comprises 7 CSR criterion layers (e.g., responsible governance and employee responsibility) and 56 index layers. 25 listed companies in China’s pharmaceutical distribution industry are chosen as research objects, and this study also establishes an evaluation model for the CSR of pharmaceutical distribution companies through the improved Criteria Importance Though Intercrieria Correlation (CRITIC) method combined with The Technique for Order Preference by Similarity to Ideal Solution (TOPSIS) method. The empirical analysis reveals that the responsible governance criterion layer and the social development criterion layer demonstrate the best performance, while the supplier, customer and patient responsibility criterion layer exhibit the worst performance.

Impact of H1N1, H7N9, ASFV, dengue virus and COVID-19 on pharmaceutical manufacturing firms' R&D investments and economic consequences: Evidence from China

Objective:To determine the impact of major disease epidemics on pharmaceutical manufacturing firms'Research&Development(R&D)investments and economic consequences.Methods:The sample consists of 1582 firm-year observations from 2009 to 2022 in China,of which,26.6%of pharmaceutical companies are involved in the diagnosis and treatment of prevalent diseases.Linear models using R&D investments,patent applications,operating performances and stock returns as dependent variables are constructed separately to examine the response of pharmaceutical companies to disease epidemics and the resulting economic consequences.Results:The prevalence of five major diseases led to a 17.5%increase in the amount of R&D investment and an 87.8%rise in the ratio of R&D investment to total assets by disease-related pharmaceutical companies,compared to unrelated pharmaceutical companies.Further evidence indicated that the patent applications for disease-related firms increased by 44.3%relative to unrelated firms after the epidemics.Though the impacts of the epidemics on firms’operating performances were insignificant in the short term,a major disease epidemic was associated with an increase in stock returns of 67.4%and 44.6%,respectively,as measured by the capital asset pricing model and Fama-French five-factor model.Additional analysis revealed that the impacts of the epidemics on R&D investments and patent applications were more pronounced for non-state-owned enterprises than state-owned enterprises.Conclusions:This study demonstrates that disease-related pharmaceutical firms respond to the disease epidemics through increasing R&D investment.More patent applications and higher market value are the main gains from the firms’increased investments in R&D following the epidemic,rather than the improvements of short-term operating performances.

Antidepressant Effect of Mongolian Pharmaceutical Betel Shisanwei Ingredient Pills and Its Improvement Effect on Depressive Syndromes

[Objectives]To analyze the effect of Mongolian pharmaceutical Betel Shisanwei Ingredient Pills in the clinical treatment of patients with depression.[Methods]From June 2020 to May 2021,64 patients with depression who received treatment in Inner Mongolia Minzu University were selected to participate in this study.These patients were randomly numbered from 1 to 64,and then divided into two groups according to the principle of odd or even number.Patients with odd number were regarded as the reference group,and treated by western medicine fluoxetine;patients with even number were regarded as the study group,and treated by Mongolian pharmaceutical Betel Shisanwei Ingredient Pills.The therapeutic effects of the two groups of patients were compared.[Results]Before treatment,there was no significant difference in the scores of patients'depressive syndromes between the two groups(P>0.05).After treatment,there were two significant changes in comprehensive score of depressive symptoms in both groups.Compared with before treatment,the data of the same group after treatment decreased significantly.Comparison between the two groups showed that the score of patients'depressive syndromes in the study group(13.28±5.49)was significantly lower than that in the reference group(18.46±6.51),and the overall response rate of treatment in the study group(96.88%,31/32)was obviously higher than that in the reference group(75.00%,24/32),showing statistically significant differences(P<0.05).[Conclusions]In the treatment of depression,Mongolian medicine therapy can significantly improve the depressive syndromes in patients,with more prominent curative effects,and is worthy of promotion and application.

Research on nanosciences involvement in pharmaceutical education should be reinforced

Inclusion of nanoscience in pharmaceutical education should be reinforced,in order to match the demand of current pharmaceutical talent cultivation.

Comprehensive Physicochemical Profiling and Characterization of Neem Plant Leaf Extracts: Insights for Pharmaceutical & Biomedical Applications

This study presents a comprehensive physicochemical analysis of neem plant leaf extracts with a focus on their potential applications in pharmaceutical and biomedical contexts. Utilizing the soxhlet extraction method with n-hexane as the solvent, the study investigated the quantitative and qualitative composition of neem leaf extracts in reference to concentrations. The results revealed a diverse array of compounds, including cyanogenic glycoside, cardiac glycoside, tannin, steroids, phytate, flavone, oxalate, rutin, lunamarin, catechin, spatein, naringin, resveratrol, kaempferol, flavonones, epicatechin, and epihedrine, with notable concentrations. Further analyses indicated shared physicochemical properties, such as carboxyl and hydroxyl groups. Qualitative assessments affirmed the presence of flavonoid and phenolic compounds, while FTIR analysis confirmed the existence of carboxyl and hydroxyl groups. These findings emphasize the potential use of neem leaves as pharmaceutical raw materials due to their antioxidant-rich content. Additionally, the study explored the density, viscosity, saponification value, and foaming power of neem leaf extracts, providing insights into their industrial applicability. GC-MS analyses highlighted the presence of significant chemical compounds, with potential therapeutic implications. Mineral analysis demonstrated essential elements for human and animal nutrition. This study underscores neem plant leaves’ multifaceted potential across pharmaceutical, herbal medicine, cosmetic, and functional food sectors. It lays a solid foundation for further research into the specific health benefits, offering valuable insights for harnessing neem leaves’ potential in innovative products and treatments.

Optimization of a Method for the Simultaneous Determination of Phloroglucinol and Trimethylphloroglucinol by High Performance Liquid Chromatography in Routine Use in a Pharmaceutical Industry in Abidjan

In order to provide the population with safe, effective and good quality medicines, the pharmaceutical industries, before releasing batches of their products into the pharmaceutical circuit, put in place internal dosage methods to control the quality of these products. The present study consisted in optimizing a method for the simultaneous determination of Phloroglucinol (PHG) and Trimethylphloroglucinol (TPH) by high performance liquid chromatography (HPLC) routinely used in a pharmaceutical industry located in a township in Abidjan (Ivory Coast). The basic chromatographic conditions were those routinely used for the determination of these two molecules: mobile phase: acetonitrile/water (60/40), stationary phase (C18 BDS Hypersil 250 mm * 4.6 mm - 5 μm), detection wavelength (265 nm), flow rate, injection volume and run time configured at the equipment level were respectively 1 mL/min, 10 μL and 8 min. The method of preparation of the analytes (PHG and TPHG) was also applied by the pharmaceutical industry. The application of these different parameters at the equipment level made it possible to determine a chromatogram which highlights three chromatographic peaks with respective retention times (RT) of 0.773 min (unidentified compound), 2.275 min (PHG) and 7.269 min for an analysis time of 8 min with a better resolution of the peaks and baseline. The progressive optimization of different parameters such as the stationary phase (C18 YMC 150 mm * 4.6 mm - 3 μm), the proportion of the mobile phase: acetonitrile/water (80/20), the flow rate impelled by the pump (0.8 mL/min) and the modification of the analyte preparation mode (same amount of PHG and TPHG in a 50 mL volumetric flask) resulted in a final chromatogram that highlighted two chromatographic peaks at the respective RT of 2.391 min (PHG) and 3.735 min (TPHG) at a run time of 6 min. The chromatographic conditions that led to the final chromatogram can be used routinely by the pharmaceutical industry for the determination of several PHG and TPHG drug matrices after prior validation of the determination method.

Study on Carbon Emission Efficiency Evaluation and Influencing Factors of Chinese Pharmaceutical Manufacturing Industry

To measure the carbon emission efficiency of China’s pharmaceutical manufacturing industry, explore the factors affecting the carbon emission efficiency of China’s pharmaceutical manufacturing industry, and provide reference for improving the carbon emission efficiency of China’s pharmaceutical manufacturing industry and promoting the government to formulate macro policies. Based on the data of the pharmaceutical manufacturing industry in 30 provinces of China from 2010 to 2019, and based on the SBM model and ML (Malmquist-Luenberger) index model, the carbon emission efficiency of the pharmaceutical manufacturing industry was calculated and its dynamic change was investigated, and the Tobit model was further used to explore the influencing factors of the carbon emission efficiency of the pharmaceutical manufacturing industry. The carbon emission efficiency of China’s inter-provincial pharmaceutical manufacturing industry has steadily improved. The carbon emission efficiency of the eastern region is higher than that of the western region, and that of the western region is higher than that of the central region. The eastern region is dominated by technological progress, and there is room for improvement in technological efficiency. The central and western regions are dominated by technological efficiency. Compared with technological efficiency, technological progress needs to be further improved. Environmental regulation, industrial agglomeration and technological innovation level positively affect carbon emission efficiency, while foreign investment level has no significant impact on carbon emission efficiency.

Computational Chemistry and Molecular Modeling Techniques for the Study of Micropeptin EI-964: Insights into Its Chemical Reactivity and Potential Pharmaceutical Properties

Micropeptin EI-964 is a cyclic peptide compound isolated from a marine cyanobacterium with potent inhibitory activity against serine proteases, particularly chymotrypsin and trypsin. It has shown promising activity against various cancer cell lines, making it a candidate for drug development. The unique structure and activity of Micropeptin EI-964 make it a promising lead compound for the development of novel serine protease inhibitors and anti-cancer drugs. Computational Chemistry and Molecular Modeling techniques can provide valuable insights into the chemical reactivity and pharmaceutical properties of Micropeptin EI-964, guiding the design and development of new compounds with enhanced bioactivity and improved drug-like properties.

Research on the Impact of Independent R&D and Collaborative Innovation on Economic Performance in China’s pharmaceutical Industry

Objective To study the impact of independent R&D and collaborative innovation on economic performance in the pharmaceutical industry.Methods A panel regression model was established by selecting the panel data of China’s pharmaceutical industry from 2009 to 2019.Results and Conclusion Independent R&D and collaborative innovation of the pharmaceutical industry in eastern,central and western regions of China had a positive effect on economic performance.Besides,the promotion effect of independent R&D was greater than that of collaborative innovation.The positive driving effect of economic performance is the largest among the three regions,followed by the central and western regions.The collaborative innovation has the greatest positive effect on economic performance in the central region,followed by the eastern and western regions.

Investigation and Countermeasures of the Development of Chinese Pharmaceutical E-commerce in the B2C Model Based on PEST-SWOT Analysis

Objective To analyze the problems of pharmaceutical e-commerce and provide strategies for its development in the future B2C mode since drug network management has great potential in China.Methods By collecting,identifying,and conducting literature research,PEST-SWOT identification and positioning of pharmaceutical e-commerce in the B2C mode were carried out.Results and Conclusion A PEST-SWOT analysis matrix was established to analyze the status of B2C pharmaceutical e-commerce,and to summarize its advantages,disadvantages,opportunities and threats from four perspectives of politics,economy,society and technology.Suggestions on cultivating compound talents proficient in medicine and e-commerce,exploring online payment methods for medical insurance,integration of upstream and downstream of the industrial chain and data sharing are put forward to promote the healthy and long-term development of pharmaceutical e-commerce under the background of big data.